Abstract
Anthelmintic drug levamisole, clinically used as an immunopotentiator, has been shown to restore the decreased cellular immune response. In this experiment, levamisole was found to increase serum complement level either in guinea pig or in human without malignancy, investigated by hemolytic assay using sensitized sheep erythrocytes (EA) for the classical pathway activity and unsensitized rabbit erythrocytes (RaE) for the alternative pathway activity. Assay of complement components revealed a mild increase in Clq, C4, C3, C9, and C1-inhibitor, while no specific tendency was observed in C5, properdin and C3 activator. Although leva misole provided no effect upon serum complement activation in vitro, these evi dences suggested that levamisole might potentiate immune response of the host by elevating serum complement level.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
